"Dr. DePinho's talents and experience make him an ideal choice to lead UT MD Anderson," says UT System Chancellor Francisco G. Cigarroa, M.D. "It is because he has such deep understanding of the impact of cancer research at the patient's bedside -- and of the complexities of cancer care -- that he is so well suited to the responsibilities of leading the nation's, and in my opinion the world's, most revered cancer center."
A genetics researcher, DePinho is director of the Belfer Institute for Applied Cancer Science at the Dana-Farber Cancer Institute in Boston. He was chosen as the sole finalist on May 11, but Texas law required a waiting period before the final vote could be taken. "It is with great pride that I have accepted this solemn responsibility as it is my belief that MD Anderson -- armed with its scientific and clinical brilliance, determined spirit and singular focus on cancer -- is supremely positioned to make major progress in the prevention, detection and treatment of this disease," DePinho says.
DePinho will succeed John Mendelsohn, M.D., who announced last December his plans to step down as president. Mendelsohn, who has served as president for the past 15 years, will remain on the faculty, returning to clinical and translational research as co-director of the new Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy. Read the UT System News Release